{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:35:53Z","timestamp":1794026153798,"version":"4.8.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21778011"],"award-info":[{"award-number":["21778011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7184192"],"award-info":[{"award-number":["7184192"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7192015"],"award-info":[{"award-number":["7192015"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.biopha.2021.112338","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T21:02:19Z","timestamp":1634850139000},"page":"112338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Development and biological evaluation of AzoBGNU: A novel hypoxia-activated DNA crosslinking prodrug with AGT-inhibitory activity"],"prefix":"10.1016","volume":"144","author":[{"given":"Qi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112338_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbcan.2017.01.004","article-title":"Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling","volume":"1868","author":"Nikolova","year":"2017","journal-title":"Biochim. Biophys. Acta\u00a0Rev. Cancer"},{"key":"10.1016\/j.biopha.2021.112338_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1021\/cr941192h","article-title":"A critical appraisal of the evolution of N-nitrosoureas as anticancer drugs","volume":"97","author":"Gnewuch","year":"1997","journal-title":"Chem. Rev."},{"key":"10.1016\/j.biopha.2021.112338_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.dnarep.2019.04.007","article-title":"DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas","volume":"78","author":"Kaina","year":"2019","journal-title":"DNA Repair"},{"key":"10.1016\/j.biopha.2021.112338_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00151229","article-title":"Phase I study of intracarotid PCNU","volume":"5","author":"Stewart","year":"1987","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.biopha.2021.112338_bib5","first-page":"2695","article-title":"Synthesis and preliminary in vitro cytotoxicity evaluation of 1,3-bis-(2-propynyl)-1-nitrosourea (BPNU) and derivatives","volume":"14","author":"Gallant","year":"1994","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s002800050421","article-title":"SarCNU (2-chloroethyl-3-sarcosinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake(2) carrier, which mediates increased cytotoxicity","volume":"37","author":"Panasci","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2021.112338_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-005-9096-7","article-title":"Cystemustine in recurrent high grade glioma","volume":"79","author":"Durando","year":"2006","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.biopha.2021.112338_bib8","first-page":"5898","article-title":"DNA damage induced by a new 2-chloroethyl nitrosourea on malignant melanoma cells","volume":"50","author":"Godeneche","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jat\/33.9.595","article-title":"Synthesis of trans- and cis-4\u2032-hydroxylomustine and development of validated analytical method for lomustine and trans- and cis-4\u2032-hydroxylomustine canine plasma","volume":"33","author":"Dirikolu","year":"2009","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.biopha.2021.112338_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/mutage\/7.6.427","article-title":"Genotoxicity of tauromustine, a new water soluble taurine-based nitrosourea. I. Mutagenic and clastogenic activity of tauromustine in vitro","volume":"7","author":"Hartleyasp","year":"1992","journal-title":"Mutagenesis"},{"key":"10.1016\/j.biopha.2021.112338_bib11","first-page":"3267","article-title":"Biological activity of hydroxylated chloroethylnitrosoureas","volume":"49","author":"Zeller","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib12","first-page":"251","article-title":"Therapeutic effect of ranimustine (MCNU) on myeloproliferative disorder and chronic myelomonocytic leukemia","volume":"18","author":"Maeda","year":"1991","journal-title":"Cancer Chemother."},{"key":"10.1016\/j.biopha.2021.112338_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0192-0561(83)90057-7","article-title":"Comparative analysis of the immunopharmacological properties of three new nitrosourea analogues: RPCNU, RFCNU and chlorozotocin","volume":"5","author":"Florentin","year":"1983","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.biopha.2021.112338_bib14","first-page":"6169","article-title":"Ability of the alpha and beta anomers of chlorozotocin to kill rat 9L tumor cells in vitro","volume":"49","author":"Wong","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ab.2010.04.037","article-title":"Selection of genetically modified hematopoietic cells in vitro and in vivo using alkylating agent lysomustine","volume":"404","author":"Rozov","year":"2010","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biopha.2021.112338_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-008-9715-1","article-title":"DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response","volume":"91","author":"Bodell","year":"2009","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.biopha.2021.112338_bib17","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1021\/cr9800199","article-title":"DNA cross-linking agents as antitumor drugs","volume":"98","author":"Rajski","year":"1998","journal-title":"Chem. Rev."},{"key":"10.1016\/j.biopha.2021.112338_bib18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/tx950097g","article-title":"Reaction of N-(2-chloroethyl)-N-nitrosoureas with DNA: effect of buffers on DNA adduction, cross-linking, and cytotoxicity","volume":"9","author":"Chen","year":"1996","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biopha.2021.112338_bib19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/poc.2970","article-title":"Comparative theoretical investigation of the formation of DNA interstrand crosslinks induced by two kinds of N-nitroso compounds: nitrosoureas and nitrosamines","volume":"25","author":"Zhao","year":"2012","journal-title":"J. Phys. Org. Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/qua.24283","article-title":"A density functional theory investigation on the formation mechanisms of DNA interstrand crosslinks induced by chloroethylnitrosoureas","volume":"113","author":"Zhao","year":"2013","journal-title":"Int. J. Quantum Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib21","first-page":"221","article-title":"The induction and repair of DNA interstrand crosslinks and implications in cancer chemotherapy","volume":"16","author":"Sun","year":"2016","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10409230903501819","article-title":"DNA interstrand crosslink repair in mammalian cells: step by step","volume":"45","author":"Muniandy","year":"2010","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.biopha.2021.112338_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"Deans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2021.112338_bib24","first-page":"119","article-title":"Repair of O6-(2-chloroethyl)guanine mediates the biological effects of chloroethylnitrosoureas","volume":"62","author":"Bodell","year":"1985","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.biopha.2021.112338_bib25","first-page":"727","article-title":"Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma","volume":"1","author":"Bacolod","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2021.112338_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1098-2280(2000)35:2<71::AID-EM1>3.0.CO;2-P","article-title":"DNA repair and gene therapy: implications for translational uses","volume":"35","author":"And","year":"2000","journal-title":"Environ. Mol. Mutagen"},{"key":"10.1016\/j.biopha.2021.112338_bib27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nsmb791","article-title":"DNA binding and nucleotide flipping by the human DNA repair protein AGT","volume":"11","author":"Daniels","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.biopha.2021.112338_bib28","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.dnarep.2007.03.011","article-title":"DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy","volume":"6","author":"Tubbs","year":"2007","journal-title":"DNA Repair"},{"key":"10.1016\/j.biopha.2021.112338_bib29","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/tx200031q","article-title":"Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools","volume":"24","author":"Pegg","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biopha.2021.112338_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/14728222.11.3.349","article-title":"S-Alkylthiolation of O6-methylguanine-DNA- methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy","volume":"11","author":"Juillerat","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.biopha.2021.112338_bib31","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.4155\/fmc-2018-0069","article-title":"The specific role of O6-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy","volume":"10","author":"Sun","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib32","first-page":"3025","article-title":"Phase I clinical and pharmacological study of O-6-benzylguanine followed by carmustine in patients with advanced cancer","volume":"6","author":"Schilsky","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11060-011-0709-z","article-title":"A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high grade gliomas and brainstem gliomas: a pediatric brain tumor consortium study","volume":"106","author":"Warren","year":"2012","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.biopha.2021.112338_bib34","doi-asserted-by":"crossref","first-page":"7861","DOI":"10.1158\/1078-0432.CCR-05-0060","article-title":"Phase II trial of the O-6-alkylguanine DNA alkyltransferase inhibitor O-6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma","volume":"11","author":"Gajewski","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib35","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","article-title":"Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma","volume":"27","author":"Quinn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2021.112338_bib36","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1517\/17460441.2013.798296","article-title":"Advances in the development of hybrid anticancer drugs","volume":"8","author":"Fortin","year":"2013","journal-title":"Expert. Opin. Drug Discov."},{"key":"10.1016\/j.biopha.2021.112338_bib37","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1021\/jm049556d","article-title":"Synthesis and antitumor activity of methyltriazene prodrugs simultaneously releasing DNA-methylating agents and the anti-resistance drug O6-benzylguanine","volume":"47","author":"Wanner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib38","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bmcl.2004.12.015","article-title":"Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status","volume":"15","author":"Rachid","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2021.112338_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1078-0432.CCR-06-0812","article-title":"The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive","volume":"13","author":"Qiu","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib40","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1021\/jm0600390","article-title":"The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR)","volume":"49","author":"Domarkas","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib41","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.bmc.2016.03.041","article-title":"Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: designed to release a DNA cross-linking agent and an inhibitor of O6-alkylguanine-DNA alkyltransferase","volume":"24","author":"Sun","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib42","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acsmedchemlett.6b00358","article-title":"Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: BGCNU","volume":"8","author":"Wang","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2021.112338_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12885-016-2131-6","article-title":"Chemotherapy with BCNU in recurrent glioma: analysis of clinical outcome and side effects in chemotherapy-naive patients","volume":"16","author":"Jungk","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2021.112338_bib44","series-title":"World Health Organization, International Agency for Research on Cancer","first-page":"48","author":"Stewart","year":"2003"},{"key":"10.1016\/j.biopha.2021.112338_bib45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature04871","article-title":"Hypoxia signaling in cancer and approaches to enforce tumour regression","volume":"441","author":"Pouyssegur","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2021.112338_bib46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1367","article-title":"Exploiting tumour hypoxia in cancer treatment","volume":"4","author":"Brown","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2021.112338_bib47","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1039\/C8CS00304A","article-title":"Hypoxia-targeted drug delivery","volume":"48","author":"Sharma","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2021.112338_bib48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2021.112338_bib49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2021.112338_bib50","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.2013.54.3660","article-title":"Phase II study of the safety and antitumor activity of the hypoxiaactivated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma","volume":"32","author":"Chawla","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2021.112338_bib51","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1158\/1078-0432.CCR-10-1439","article-title":"Pharmacokinetic\/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors","volume":"16","author":"Hicks","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1476-5381.2012.01996.x","article-title":"EO9 (Apaziquone): from the clinic to the laboratory and back again","volume":"168","author":"Phillips","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2021.112338_bib53","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-07-0478","article-title":"Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104","volume":"13","author":"Patterson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib54","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1039\/C8CC03430C","article-title":"An azobenzene-based heteromeric prodrug for hypoxia-activated chemotherapy by regulating subcellular localization","volume":"54","author":"Li","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.biopha.2021.112338_bib55","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1021\/jm301804p","article-title":"Hypoxia-selective O-6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O-6-benzylguanine","volume":"56","author":"Zhu","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib56","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1021\/tx00034a008","article-title":"Chemical synthesis and detection of the cross-link 1-[N3- (2\u2032-deoxycytidyl)]-2-[N1-(2\u2032-deoxyguanosinyl)]ethane in DNA reacted with 1-(2- chloroethyl)-1-nitrosourea","volume":"6","author":"Bodell","year":"1993","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biopha.2021.112338_bib57","first-page":"4363","article-title":"Direct demonstration in synthetic oligonucleotides that N,N\u2032-bis(2-chloroethyl)-nitrosourea cross-links N1 of deoxyguanosine to N3 of deoxycytidine on opposite strands of duplex DNA","volume":"59","author":"Fischhaber","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nbt765","article-title":"A general method for the covalent labeling of fusion proteins with small molecules in vivo","volume":"21","author":"Keppler","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2021.112338_bib59","first-page":"135","article-title":"N-(2-chloroethyl)-N\u2032-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells","volume":"58","author":"Aquilina","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib60","doi-asserted-by":"crossref","first-page":"10143","DOI":"10.1016\/j.biomaterials.2013.09.034","article-title":"Porous chitosan-hyaluronic acid scaffolds as a mimic of glioblastoma microenvironment ECM","volume":"34","author":"Florczyk","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2021.112338_bib61","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1021\/tx500143b","volume":"27","author":"Sun","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biopha.2021.112338_bib62","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1021\/ac7023969","article-title":"LC-MS\/MS for the detection of DNA interstrand cross-links formed by 8-methoxypsoralen and UVA irradiation in human cells","volume":"80","author":"Cao","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib63","first-page":"5656","article-title":"Enhanced sensitivity of 32P-postlabeling analysis of aromatic carcinogen-DNA adducts","volume":"45","author":"Gupta","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib64","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/tx400235x","article-title":"Quantitation of pyridyloxobutyl-DNA adducts in tissues of rats treated chronically with (R)- or (S)-N\u2032-nitrosonornicotine (NNN) in a carcinogenicity study","volume":"26","author":"Zhao","year":"2013","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biopha.2021.112338_bib65","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/nar\/28.2.393","article-title":"Crystal structure of the human O6-alkylguanine-DNA alkyltransferase","volume":"28","author":"Wibley","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2021.112338_bib66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0045-6535(99)00226-X","article-title":"Non-enzymatic reduction of azo dyes by NADH","volume":"40","author":"Nam","year":"2000","journal-title":"Chemosphere"},{"key":"10.1016\/j.biopha.2021.112338_bib67","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4155\/fmc-2018-0511","article-title":"NBGNU: a hypoxia-activated tripartite combi-nitrosourea prodrug overcoming AGT-mediated chemoresistance","volume":"11","author":"Ge","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.biopha.2021.112338_bib68","first-page":"697","article-title":"Comparative cytotoxicity of carmustine (BCNU), nimustine (ACNU) and elmustine (HeCNU) after depletion of O6-alkylguanine-DNA alkyltransferase (O6-AGT)","volume":"22","author":"B\u00fcch","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF01400647","article-title":"Potential of O6-methylguanine or O6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain-tumors","volume":"128","author":"Mineura","year":"1994","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.biopha.2021.112338_bib70","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cbic.200600495","article-title":"Redox potential of azobenzene as an amino acid residue in peptides","volume":"8","author":"Boulegue","year":"2007","journal-title":"ChemBioChem"},{"key":"10.1016\/j.biopha.2021.112338_bib71","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.4161\/cc.20862","article-title":"Chloroethylnitrosourea-induced cell death and genotoxicity: cell cycle dependence and the role of DNA double-strand breaks, HR and NHEJ","volume":"11","author":"Nikolova","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.biopha.2021.112338_bib72","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2021.112338_bib73","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2131\/jts.36.695","article-title":"Mechanisms of neurotoxicity induced in the developing brain of mice and rats by DNA-damaging chemicals","volume":"36","author":"Doi","year":"2011","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.biopha.2021.112338_bib74","doi-asserted-by":"crossref","first-page":"11886","DOI":"10.1158\/0008-5472.CAN-07-2964","article-title":"Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks","volume":"67","author":"Batista","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib75","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.3390\/ijms21186806","article-title":"Three-dimensional cell cultures as an in vitro tool for prostate cancer modeling and drug discovery","volume":"21","author":"Fontana","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.112338_bib76","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3390\/pharmaceutics12121186","article-title":"Three-dimensional spheroids as in vitro preclinical models for cancer research","volume":"12","author":"Pinto","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2021.112338_bib77","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13046-020-01583-1","article-title":"Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models","volume":"39","author":"Bhattacharya","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2021.112338_bib78","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1535-7163.MCT-15-0963","article-title":"Hypoxia-driven mechanism of vemurafenib resistance in melanoma","volume":"15","author":"Qin","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2021.112338_bib79","first-page":"2027","article-title":"Quantification of meCCNU induced dC-dG crosslinks in oligonucleotide duplex by liquid chromatography\/electrospray ionization tandem mass spectrometry, Rapid Commun","volume":"25","author":"Bai","year":"2011","journal-title":"Mass Spectrom."},{"key":"10.1016\/j.biopha.2021.112338_bib80","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/rcm.6800","article-title":"Quantification of DNA interstrand crosslinks induced by ACNU in NIH\/3T3 and L1210 cells using high-performance liquid chromatography\/electrospray ionization tandem mass spectrometry","volume":"28","author":"Li","year":"2014","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.biopha.2021.112338_bib81","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/molecules21070823","article-title":"Idetification of the structural features of guanine derivatives as MGMT inhibitors using 3D-QSAR modeling combined with molecular docking","volume":"21","author":"Sun","year":"2016","journal-title":"Molecules"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:40:47Z","timestamp":1777574447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221011227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":81,"alternative-id":["S0753332221011227"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112338","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and biological evaluation of AzoBGNU: A novel hypoxia-activated DNA crosslinking prodrug with AGT-inhibitory activity","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112338"}}